MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Rhythm Pharmaceuticals Inc

Fermé

SecteurSoins de santé

46.8 -6.01

Résumé

Variation du prix de l'action

24h

Actuel

Min

45.99

Max

49.79

Chiffres clés

By Trading Economics

Revenu

385K

-43M

Ventes

8.6M

42M

BPA

-0.72

Marge bénéficiaire

-103.495

Employés

283

EBITDA

806K

-38M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+50.9% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

104M

3.5B

Ouverture précédente

52.81

Clôture précédente

46.8

Sentiment de l'Actualité

By Acuity

50%

50%

166 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 avr. 2025, 23:04 UTC

Actualités

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 avr. 2025, 22:40 UTC

Principaux Mouvements du Marché

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 avr. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 avr. 2025, 18:51 UTC

Acquisitions, Fusions, Rachats

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

4 avr. 2025, 00:00 UTC

Actualités

Resistance Is Futile, Make a Deal: Trump's Tariff Message to the World -- WSJ

3 avr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 avr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 avr. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 21:43 UTC

Actualités
Résultats

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 avr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 avr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 avr. 2025, 20:34 UTC

Actualités

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 avr. 2025, 20:23 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 20:15 UTC

Acquisitions, Fusions, Rachats

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 avr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 avr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 avr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 avr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 avr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 avr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 avr. 2025, 18:38 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 18:30 UTC

Actualités

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 avr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 avr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 avr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

Comparaison

Variation de prix

Rhythm Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

50.9% hausse

Prévisions sur 12 Mois

Moyen 75.18 USD  50.9%

Haut 94 USD

Bas 60 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

48.23 / 53.44Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

166 / 386Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.